HLA disease association and protection in HIV infection among African Americans and Caucasians. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HLA disease association and protection in HIV infection among African Americans and Caucasians.

Pathobiology. 1991;59(5):324-8. Unique Identifier : AIDSLINE MED/92000246
Cruse JM; Brackin MN; Lewis RE; Meeks W; Nolan R; Brackin B; University of Mississippi Medical Center, Jackson.

Abstract: In a previous investigation, we demonstrated an increased progression of overt AIDS in the African American population compared to the Caucasian population as reflected by the significantly lower absolute number of CD4+ lymphocytes detected in the African American population in an earlier study. The present study elucidates some of the possible genetic factors which may contribute to disease association or protection against HIV infection. The HLA phenotypes expressed as A, B, C, DR and DQw antigens were revealed by the Amos-modified typing procedure. NIH scoring was utilized to designate positive cells taking up trypan blue. A test of proportion equivalent to the chi 2 approximation was used to compare the disease population (n = 62; 38 African Americans, 24 Caucasians) to race-matched normal heterosexual local controls (323 African Americans, 412 Caucasians). Significant p values were corrected for the number of HLA antigens tested. HLA markers associated with possible protection from infection for African Americans were Cw4 and DRw6, whereas Caucasians expressed none. Disease association markers present in the African American population were A31, B35, Cw6, Cw7, DR5, DR6, DRw11, DRw12, DQw6 and DQw7, whereas in the Caucasian population A28, Aw66, Aw48, Bw65, Bw70, Cw7, DRw10, DRw12, DQw6 and DQw7 were demonstrated. The highest phenotypic frequency for a disease association marker in the study was for HLA-DR5 (62.9%) in the HIV-infected African American population without Kaposi's sarcoma compared to a frequency of 28.9% for the regional control group (p = 0.0012). We conclude that genetic factors do have a role in HIV infection since only 50-60% of those exposed to the AIDS virus will become infected.
Keywords: Blotting, Western Caucasoid Race/*GENETICS Comparative Study Disease Susceptibility Enzyme-Linked Immunosorbent Assay Genetic Markers/GENETICS/IMMUNOLOGY Human HIV Infections/COMPLICATIONS/EPIDEMIOLOGY/*PREVENTION & CONTROL HLA Antigens/GENETICS/*IMMUNOLOGY HLA-A Antigens/GENETICS/IMMUNOLOGY HLA-B Antigens/GENETICS/IMMUNOLOGY HLA-C Antigens/GENETICS/IMMUNOLOGY HLA-DQ Antigens/GENETICS/IMMUNOLOGY HLA-DR Antigens/GENETICS/IMMUNOLOGY Incidence Longitudinal Studies Negroid Race/*GENETICS Phenotype Sarcoma, Kaposi's/COMPLICATIONS/EPIDEMIOLOGY/IMMUNOLOGY Support, U.S. Gov't, P.H.S. United States/EPIDEMIOLOGY JOURNAL ARTICLE

KWDblotting,westerncaucasoidrace/KWDgeneticscomparativestudydiseasesusceptibilityenzyme-linkedimmunosorbentassaygeneticmarkers/genetics/immunologyhumanhivinfections/complications/epidemiology/KWDprevention&controlhlaantigens/genetics/KWDimmunologyhla-aantigens/genetics/immunologyhla-bantigens/genetics/immunologyhla-cantigens/genetics/immunologyhla-dqantigens/genetics/immunologyhla-drantigens/genetics/immunologyincidencelongitudinalstudiesnegroidrace/KWDgeneticsphenotypesarcoma,kaposi's/complications/epidemiology/immunologysupport,uKWDsKWDgov't,pKWDhKWDsKWDunitedstates/epidemiologyjournalarticle
920130
M9210743

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .